文献速递胸部肿瘤

每周两次脉冲联合每日低剂量厄洛替尼作为EGFR突变肺癌初始治疗的1期研究

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.
PubMed 文献 · Ann Oncol · 2017-01-01

这项1期研究评估每周两次脉冲联合每日低剂量厄洛替尼治疗EGFR突变肺癌的毒性、药代动力学和疗效。最大耐受剂量为第1-2天1200毫克、第3-7天每日50毫克;客观缓解率74%(95%CI 60-84%),中位无进展生存9.9个月(95%CI 5.8-15.4个月),研究期间无患者出现未经治疗的中枢神经系统转移进展或新发中枢神经系统病灶(0%,95%CI 0-13%)。作者结论认为该方案耐受良好,但未改善无进展生存,也未阻止EGFR T790M出现。

要点

  • 最大耐受剂量为厄洛替尼第1-2天1200毫克、第3-7天每日50毫克,每周给药。
  • 1例完全缓解和24例部分缓解,客观缓解率74%(95%CI 60-84%)。
  • 研究期间无患者出现未经治疗的中枢神经系统转移进展或新发中枢神经系统病灶(0%,95%CI 0-13%)。

核心结论

  • 该方案是抗癌EGFR酪氨酸激酶抑制剂脉冲联合每日低剂量给药的首个临床实施。
  • 该基于演化模型的给药方案耐受良好,但未改善无进展生存,也未阻止EGFR T790M出现,可能因厄洛替尼血清峰值浓度不足。
  • 该给药方案在所有患者中阻止了未经治疗的中枢神经系统转移进展及任何新发中枢神经系统转移。

研究设计与样本

  • 1期剂量递增研究,入组34例EGFR突变肺癌患者,评估每周两次脉冲联合每日低剂量厄洛替尼的毒性、药代动力学和疗效。
  • 评估6个递增的厄洛替尼脉冲剂量;入组时11例(32%)患者有脑转移。

主要发现

  • 剂量递增中观察到3例剂量限制性毒性:转氨酶升高、黏膜炎和皮疹。
  • 最常见毒性(任何级别)为皮疹、腹泻、恶心、乏力和黏膜炎。
  • 1例完全缓解和24例部分缓解(74%,95%CI 60-84%)。
  • 中位无进展生存9.9个月(95%CI 5.8-15.4个月)。
  • 18例进展时活检患者中,78%(95%CI 54-91%)检出EGFR T790M。

关键数值与推荐

  • 最大耐受剂量为厄洛替尼第1-2天1200毫克、第3-7天每日50毫克,每周给药。
  • 客观缓解率74%(95%CI 60-84%),包括1例完全缓解和24例部分缓解。
  • 中位无进展生存9.9个月(95%CI 5.8-15.4个月)。
  • 研究期间未经治疗的中枢神经系统转移进展或新发中枢神经系统病灶为0%(95%CI 0-13%)。
  • 进展时活检的18例患者中EGFR T790M检出率78%(95%CI 54-91%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出该方案未改善无进展生存,也未阻止EGFR T790M出现,可能因厄洛替尼血清峰值浓度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with EGFR-mutant lung cancers treated with EGFR tyrosine kinase inhibitors (TKIs) develop clinical resistance, most commonly with acquisition of EGFR T790M. Evolutionary modeling suggests that a schedule of twice weekly pulse and daily low-dose erlotinib may delay emergence of EGFR T790M. Pulse dose erlotinib has superior central nervous system (CNS) penetration and may result in superior CNS disease control. METHODS: We evaluated toxicity, pharmacokinetics, and efficacy of twice weekly pulse and daily low-dose erlotinib. We assessed six escalating pulse doses of erlotinib. RESULTS: We enrolled 34 patients; 11 patients (32%) had brain metastases at study entry. We observed 3 dose-limiting toxicities in dose escalation: transaminitis, mucositis, and rash. The MTD was erlotinib 1200 mg days 1-2 and 50 mg days 3-7 weekly. The most frequent toxicities (any grade) were rash, diarrhea, nausea, fatigue, and mucositis. 1 complete and 24 partial responses were observed (74%, 95% CI 60-84%). Median progression-free survival was 9.9 months (95% CI 5.8-15.4 months). No patient had progression of an untreated CNS metastasis or developed a new CNS lesion while on study (0%, 95% CI 0-13%). Of the 18 patients with biopsies at progression, EGFR T790M was identified in 78% (95% CI 54-91%). CONCLUSION: This is the first clinical implementation of an anti-cancer TKI regimen combining pulse and daily low-dose administration. This evolutionary modeling-based dosing schedule was well-tolerated but did not improve progression-free survival or prevent emergence of EGFR T790M, likely due to insufficient peak serum concentrations of erlotinib. This dosing schedule prevented progression of untreated or any new central nervous system metastases in all patients.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Yu HA, Sima C, Feldman D, et al. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol. 2017. PMID: 28073786. doi:10.1093/annonc/mdw556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。